Japanese health tech company Ubie is looking to fuel its US expansion with a $19 million Series C round

Killeda Tokyo-based startup providing an AI-based symptom-checking app and hospital SaaS products has closed a $19 million expansion for the previous round of Serie C. This brings the health tech startup’s total Series C funding to $45.2 million.

The expanded round consists of 90% equity and 10% debt financing, according to Ubie co-founder and CEO Kota Kuto. With this round, Ubie has raised a total of $76 million since its inception in 2017.

The startup declined to comment on its company’s valuation, but a source familiar with the situation, who spoke on condition of anonymity, told TechCrunch that its valuation is now estimated at $250 million. Investors in the latest funding include Sogo Medical, AAIC Investment, Japan Impact Investment, Rakuten Capital, Shoko Chukin Bank, Japan Finance Corporation and Mizuho Bank.

Ubie plans to use the proceeds to expand its healthcare platform and boost its entry into the US after entering Singapore in August. Startup has started its symptom check application earlier this year in the US and opened a US subsidiary in October. Kuto told TechCrunch that Singapore’s medical system is similar to Japan’s given its geographic and cultural background, so the company decided that Singapore would be “an appropriate first step for global expansion.”

The outlet is in discussions with pharmaceutical companies to increase partnerships, many of which have offices on the East Coast, Couto explained. It expects to finalize and announce several partnership deals early next year, Couto added.

Ubie isn’t the only health tech company developing an AI-powered symptom checker for consumers. A Boston-based startup, Good healthbuilt an AI-powered symptom checker app; Based in Berlin Hell health also developed an AI-driven symptom assessment app; and IBM Medic helps people with symptom assessment. Kuto pointed out, as a distinction, that Ubie offers a B2B product called Ubie for Hospital, also known as AI Monshin, and a B2C application for individual users. Ubie for Hospitals, which allows doctors to reduce their time taking notes from patients’ histories, is a medical questionnaire software through which patients can conduct a pre-interview via tablet while they wait before meeting with doctors.

“Based on data extracted from approximately 50,000 medical research articles [created by more than 50 physicisans]A. I. Monshin [automatically] selects and asks about 20 questions from 3,500 types of question data,” Kota said.

Co-founded by doctor Yoshinori Abe and engineer Kubo, Ubie claims more than 1,100 medical institutions in Japan use Ubie’s AI Monshin. The company also has more than 7 million monthly active users (MAU) of its symptom checker app. Ubie employs about 200 people.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *